iCardiac Technologies Inc.

Few issues are more nettlesome in drug development than the potential for a new drug to unleash rare but potentially lethal heart-rhythm irregularities. The industry has a glaring need for improved cardiac safety testing. iCardiac Technologies hopes to turn that need into a service business with its proprietary algorithms and advanced electrocardiogram biomarkers.

150 Allens Creek Road

Rochester, NY 14618

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

More from Scrip

France’s AB Science Plots Pivotal Masitinib Trial In Prostate Cancer

 
• By 

Still holding out hope after multiple rejections for the tyrosine kinase inhibitor.

In Brief: Concentra Snaps Up Struggling IGM Biosciences In Latest Biotech Deal

 

Concentra Biosciences is acquiring struggling IGM Biosciences for $1.25 per share plus a contingent value right, with the deal expected to close in August 2025.

Pipeline Watch: Ten Approvals And Eleven Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.